Evaluation of treatment-resistant schizophrenia
- PMID: 9366002
- DOI: 10.1093/schbul/23.4.663
Evaluation of treatment-resistant schizophrenia
Abstract
A systematic approach to the evaluation and characterization of treatment resistance in schizophrenia has become increasingly important since the introduction of clozapine, risperidone, and olanzapine. The need for accurate evaluation will increase with the introduction of the next generation of antipsychotic medications. People with schizophrenia may manifest a poor response to therapy secondary to intolerance of medication, poor compliance, or inappropriate dosing, as well as true resistance of their illness to antipsychotic drug therapy. Clinicians facing the decision of when to change from one antipsychotic to another must clearly understand the appropriate length of a trial and what target symptoms respond to antipsychotics in order to maximize the response in patients with treatment-resistant schizophrenia.
Similar articles
-
Management of treatment resistance in schizophrenia.Biol Psychiatry. 2001 Dec 1;50(11):898-911. doi: 10.1016/s0006-3223(01)01271-9. Biol Psychiatry. 2001. PMID: 11743944 Review.
-
An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.Hum Psychopharmacol. 2011 Jan;26(1):81-5. doi: 10.1002/hup.1173. Epub 2011 Feb 9. Hum Psychopharmacol. 2011. PMID: 23055416 Review.
-
Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.Psychopharmacology (Berl). 2019 Feb;236(2):545-559. doi: 10.1007/s00213-018-5133-z. Epub 2018 Nov 30. Psychopharmacology (Berl). 2019. PMID: 30506237 Review.
-
Combination of "atypical" antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder.Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jan;28(1):89-98. doi: 10.1016/j.pnpbp.2003.09.024. Prog Neuropsychopharmacol Biol Psychiatry. 2004. PMID: 14687862 Review.
-
[A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].Neuropsychopharmacol Hung. 2007 Oct;9(3):115-24. Neuropsychopharmacol Hung. 2007. PMID: 18399029 Hungarian.
Cited by
-
Experiences, attitudes, and perceptions of caregivers of individuals with treatment-resistant schizophrenia: a qualitative study.BMC Psychiatry. 2018 Aug 13;18(1):253. doi: 10.1186/s12888-018-1833-5. BMC Psychiatry. 2018. PMID: 30103719 Free PMC article.
-
Patients with poor response to antipsychotics have a more severe pattern of frontal atrophy: a voxel-based morphometry study of treatment resistance in schizophrenia.Biomed Res Int. 2014;2014:325052. doi: 10.1155/2014/325052. Epub 2014 Jul 23. Biomed Res Int. 2014. PMID: 25157354 Free PMC article.
-
A modelling approach to estimate the prevalence of treatment-resistant schizophrenia in the United States.PLoS One. 2020 Jun 4;15(6):e0234121. doi: 10.1371/journal.pone.0234121. eCollection 2020. PLoS One. 2020. PMID: 32497106 Free PMC article.
-
Insights on current and novel antipsychotic mechanisms from the MAM model of schizophrenia.Neuropharmacology. 2020 Feb;163:107632. doi: 10.1016/j.neuropharm.2019.05.009. Epub 2019 May 8. Neuropharmacology. 2020. PMID: 31077730 Free PMC article. Review.
-
Efficacy and safety of treating patients with refractory schizophrenia with antipsychotic medication and adjunctive electroconvulsive therapy: a systematic review and meta-analysis.Shanghai Arch Psychiatry. 2015 Aug 25;27(4):206-19. doi: 10.11919/j.issn.1002-0829.215093. Shanghai Arch Psychiatry. 2015. PMID: 26549957 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical